Sellas Stock 346% Year Near Final REGAL Deaths Ahead
Sellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
This analysis points to fund families that consistently stood out in index fund history, helping you recognize dominant players over time.
25,021 articlesSellas Life Sciences has surged 346% over the past year as its REGAL trial for a WT1-targeting cancer vaccine moves t...
Airports face ongoing delays as spring travel returns. Enrolling in TSA PreCheck may help speed security lines for ti...
Two big reasons explain why the fear around IBM's COBOL future might be overstated. This piece breaks down why COBOL ...
TD Cowen boosts its Match Group target on better Tinder metrics, while UBS stays cautious. The market tests whether T...
Bank of America signals a noticeable pullback in card use across its customers, adding to a growing picture of cautio...
Ferrari delivered a quarter that topped estimates, yet the stock moved lower. This piece deciphers what drove the bea...
Real Brokerage deepens its Kansas City presence by adding Chartwell Realty, bringing 150 agents and cementing its sta...
Rocket Lab is expanding by purchasing a competing space systems group for up to $60 million. This article breaks down...
KeyBanc boosted its outlook on CrowdStrike, lifting the price target to $700 after signals from the Mythos conference...
ThredUp's chief argues that a permanent four-day workweek provides a competitive edge in attracting talent. The broad...
Rocket Lab has surged on new contracts and a growing backlog, yet investors wonder if the rally can last. This guide ...
Bitcoin sits at a pivotal crossroads as on-chain and technical indicators converge around the $70K realized price ban...